ASCO GU 2023

ASCO GU 2023
February 16-18, 2023
Moscone Center, San Francisco, California

American Society of Clinical Oncology Genitourinary Cancers Symposium.

Explore more information for Gilead Oncology therapies
Results (5)

TROPHY-U-01 Cohort 2, a Phase 2 Study of Sacituzumab Govitecan in Platinum-Ineligible Patients With Metastatic Urothelial Cancer who Progressed After Prior Checkpoint Inhibitor Therapy

Primary Analysis of TROPHY-U-01 Cohort 3, a Phase 2 Study of Sacituzumab Govitecan in Combination With Pembrolizumab in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Therapy

TROPHY-U-01 Cohort 5: Evaluation of Maintenance Sacituzumab Govitecan Plus Zimberelimab, Zimberelimab, or Avelumab in Cisplatin-Eligible Patients With Unresectable or Metastatic Urothelial Cancer

Updated Outcomes in TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Chemotherapy and a Checkpoint Inhibitor

TROPHY-U-01 Cohort 6: Sacituzumab Govitecan, Sacituzumab Govitecan Plus Zimberelimab, Sacituzumab Govitecan Plus Zimberelimab Plus Domvanalimab, or Carboplatin + Gemcitabine in Cisplatin-Ineligible Patients With Treatment-Naïve Metastatic